Contact Lens Wear Is Associated with Decrease of Meibomian Glands

Arita, Reiko; Itoh, K.; Inoue, Kenji; Kuchiba, Aya; Yamaguchi, Takuhiro; Amano, Shiro

doi:10.1016/j.ophtha.2008.10.012

Cited by 250 publications

(291 citation statements)

References 16 publications

Supporting

Mentioning

249

Contrasting

Unclassified

Order By: Relevance

“…113,114 Using the new technology, the authors reported that CL wear accelerates age-related changes in the meibomian glands. 115 They also found that CL wearers with an average age of 32 years demonstrated an average meiboscore similar to that observed in a 60-to 90-year-old age group from the normal population. 115 Additionally, loss of meibomian glands depends on the duration of CL wear, but not on the CL materials (e.g., GP vs. conventional CLs).…”

Section: Meibomian Gland Dropoutsupporting

confidence: 59%

“…115 They also found that CL wearers with an average age of 32 years demonstrated an average meiboscore similar to that observed in a 60-to 90-year-old age group from the normal population. 115 Additionally, loss of meibomian glands depends on the duration of CL wear, but not on the CL materials (e.g., GP vs. conventional CLs). 115 It is unclear whether MGDo can be recovered after CL cessation.…”

Section: Meibomian Gland Dropoutsupporting

confidence: 59%

“…11), particularly at the distal end, producing significantly greater effects in the upper than in the lower eyelid, supporting a mechanical theory. 115 However, other authors reported no association between MGDo in the lower eyelid and CL wear. 117 The disagreement in study results is possibly because of the authors from the latter study not examining or imaging the full extent of both upper and lower eyelids, but rather only the central portion of the lower eyelid.…”

Section: Meibomian Gland Dropoutmentioning

confidence: 97%

“…115 Additionally, loss of meibomian glands depends on the duration of CL wear, but not on the CL materials (e.g., GP vs. conventional CLs). 115 It is unclear whether MGDo can be recovered after CL cessation.…”

Section: Meibomian Gland Dropoutmentioning

confidence: 99%

“…If flexing of ultrathin hydrogel lenses is to be blamed, we may assume that GP lenses should induce a different rate of MGDos, and yet one study did not find statistically significant differences in MGDo between GP and conventional CLs. 115 Further investigation with modern technology is needed to elucidate the mechanisms responsible for meibomian gland morphologic changes because of CL wear, to examine whether these changes differ between conventional and SiHy CLs or between different wearing modalities, and to determine how these anatomical changes affect the function (e.g., gland expressibility, lipid compositions) of meibomian glands and lens-wearing comfort.…”

Section: Meibomian Gland Dropoutmentioning

confidence: 99%

See 4 more Smart Citations

Mechanical Complications Induced by Silicone Hydrogel Contact Lenses

Lin

Yeh

2013

Eye &Amp; Contact Lens: Science &Amp; Clinical Practice

View full text Add to dashboard Cite

Section: Meibomian Gland Dropoutsupporting

confidence: 59%

Section: Meibomian Gland Dropoutsupporting

confidence: 59%

Section: Meibomian Gland Dropoutmentioning

confidence: 97%

Section: Meibomian Gland Dropoutmentioning

confidence: 99%

Section: Meibomian Gland Dropoutmentioning

confidence: 99%

See 3 more Smart Citations

Mechanical Complications Induced by Silicone Hydrogel Contact Lenses

Lin

Yeh

2013

Eye &Amp; Contact Lens: Science &Amp; Clinical Practice

View full text Add to dashboard Cite

The Effects of Insulin-like Growth Factor 1 and Growth Hormone on Human Meibomian Gland Epithelial Cells

Ding

Sullivan

2014

JAMA Ophthalmol

View full text Add to dashboard Cite

IMPORTANCE A phase 1 study has reported that dry eye disease is the most common adverse effect of human exposure to the antibody figitumumab, an anticancer drug that prevents insulin-like growth factor 1 (IGF-1) from binding to its receptor. We hypothesized that the mechanism underlying this effect is the inhibition of IGF-1 action in epithelial cells of the meibomian gland.OBJECTIVES To test the hypothesis that IGF-1 stimulates meibomian gland function in vitro and to examine whether growth hormone, a closely related hormone of IGF-1, has the same effect.DESIGN, SETTING, AND MATERIAL Immortalized human meibomian gland epithelial cells were cultured in the presence or the absence of IGF-1, growth hormone, and an IGF-1 receptor-blocking antibody. Signaling pathways, cell proliferation, neutral lipid staining, and a key protein involved in lipid biogenesis were evaluated.INTERVENTION Application of IGF-1 and growth hormone to human meibomian gland epithelial cells. MAIN OUTCOMES AND MEASURESImmunoblotting, cell counting, and neutral lipid staining.RESULTS Insulin-like growth factor 1 activated the phosphoinositol 3-kinase/Akt and forkhead box O1 pathways (showing a dose-dependent effect on immunoblotting), stimulated cellular proliferation (about 1.8-fold increase in cell number), increased sterol regulatory element-binding protein 1 expression (about 3-fold increase on immunoblotting), and promoted lipid accumulation in human meibomian gland epithelial cells (about 2-fold increase in lipid staining). These IGF-1 actions, which may be blocked by cotreatment with the anti-IGF-1 antibody, were accompanied by inconsistent effects on extracellular signal-regulated kinase phosphorylation. We were not able to demonstrate activation of Akt, forkhead box O1, extracellular signal-regulated kinase, Janus kinase 2, or signal transducers and activators of transcription 5, induced cell proliferation, or lipid accumulation in these cells by growth hormone application. CONCLUSIONS AND RELEVANCEOur results support the hypothesis that IGF-1 acts on human meibomian gland epithelial cells and may explain why treatment with figitumumab, the IGF-1 inhibitor, causes dry eye disease. Ophthalmic care for dry eye disease may be needed when patients with cancer undergo treatment with drugs that inhibit IGF-1 action.

show abstract